In HIV-1-infected patients receiving anti-retroviral therapy (ART), the relationship between residual viraemia and ex vivo recovery of infectious virus from latently infected CD4 cells is uncertain.
Methods
We measured residual viraemia (HIV-1 RNA copies/ml) by single-copy assay (SCA) and the latent reservoir by infectious virus recovery from resting memory CD4 cells (infectious units per million cells [IUPM]) in patients who initiated ART. We assessed immune activation by measuring CD38 expression on T-cells.
Results
Ten patients who initiated ART and maintained a plasma HIV-1 RNA level <200 copies/ml had residual viraemia and IUPM measured every 24 weeks. Five of 10 patients had longitudinal IUPM measured at weeks 24–96; the remainder had IUPM measured 1–3 times over 24–72 weeks. Analyses of 29 paired measurements revealed a positive association between level of residual viraemia and IUPM (0.56 higher log10 HIV-1 RNA copies/ml per 1 log10 higher IUPM; P=0.005). Residual viraemia level was positively associated with CD38 density and percentage on CD8+ T-cells in concurrent samples and with pre-ART HIV-1 RNA levels.
Conclusions
In patients with HIV-1 RNA levels <200 copies/ml 24–96 weeks after initiating ART, the level of viraemia is positively associated with infectious virus recovery from resting memory CD4 cells. Whether this association persists after longer-term suppressive ART needs to be determined. If additional studies show that residual viraemia measured by SCA refects the size of the latent reservoir in patients who have had virological suppression for longer periods of time, this could facilitate testing of potentially curative strategies to reduce this important reservoir.
References
1.
FinziD., BlanksonJ., SilicianoJ.D.Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med1999; 5: 512–517.
2.
PalmerS., MaldarelliF., WiegandA.Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A2008; 105: 3879–3884.
3.
AndersonJ.A., ArchinN.M., InceW.Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells. J Virol2011; 85: 5220–5223.
4.
GandhiR.T., BoschR.J., AgaE.No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. J Infect Dis2010; 201: 293–296.
5.
SilicianoJ.D., SilicianoR.F.Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol Biol2005; 304: 3–15.
6.
PalmerS., WiegandA.P., MaldarelliF.New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol2003; 41: 4531–4536.
7.
FollmannD., ProschanM., LeiferE.Multiple outputation: inference for complex clustered data by averaging analyses from independent data. Biometrics2003; 59: 420–429.
8.
ChunT.W., MurrayD., JustementJ.S.Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis2011; 204: 135–138.
9.
YuklS.A., GianellaS., SinclairE.Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis2010; 202: 1553–1561.
10.
JoosB., FischerM., KusterH.HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A2008; 105: 16725–16730.
11.
GandhiR.T., ZhengL., BoschR.J.The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med2010; 7: e1000321.
12.
ClementL.T., VinkP.E., BradleyG.E.Novel immunoregulatory functions of phenotypically distinct subpopulations of CD4+ cells in the human neonate. J Immunol1990; 145: 102–108.
13.
Rabian-HerzogC., LesageS., GluckmanE.Characterization of lymphocyte subpopulations in cord blood. Bone Marrow Transplant1992; 9Suppl 1: 64–67.
14.
DianzaniU., FunaroA., DiFrancoD.Interaction between endothelium and CD4+CD45RA+ lymphocytes. Role of the human CD38 molecule. J Immunol1994; 153: 952–959.
